Healthy Skepticism Library item: 13504
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Falit BP.
Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results.
Seton Hall Law Rev. 2007; 37:(4):969-1049
Keywords:
Clinical Protocols
Clinical Trials, Phase IV as Topic*/economics
Complementary Therapies
Continental Population Groups
Cost-Benefit Analysis
Dose-Response Relationship, Drug
Drug Approval
Drug Industry*/economics
Epidemiologic Factors
Financial Support*
Formularies
Government Regulation
Humans
Information Services*
Insurance Coverage
Insurance, Pharmaceutical Services
Motivation*
Organizational Policy
Outcome and Process Assessment (Health Care)*
Patient Selection
Pharmaceutical Preparations/adverse effects
Physician's Practice Patterns*
Private Sector
Product Surveillance, Postmarketing
Public Sector
Publication Bias
Quality Control
Research Design*
Severity of Illness Index
Time Factors
United States
United States Food and Drug Administration
